Evidence map›Paper›PMID 34260842›Full record

ArticleThe New England journal of medicine2021

Hepatocellular Carcinoma - Origins and Outcomes.

Robin K Kelley, Tim F Greten

Abstract readComment
PubMed Publisher
In one paragraph

Article in The New England journal of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Trial
  5. Review
  6. A Phase II Trial of Pembrolizumab plus Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Biliary Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Analysis of the role ofTranslational cancer research · 2024
    Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Robin K KelleyFrom the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco (R.K.K.); and the Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), and the NCI CCR Liver Cancer Program, National Institutes of Health, Bethesda, MD (T.F.G.).ORCID 0000-0002-1984-2430
Tim F GretenFrom the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco (R.K.K.); and the Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), and the NCI CCR Liver Cancer Program, National Institutes of Health, Bethesda, MD (T.F.G.).ORCID 0000-0002-0806-2535

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHumansNeoplasm Recurrence, Local

Identifiers

PMID34260842

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.